Hunan Nanxin Pharmaceutical Co., Ltd. Progress Announcement on Repurchasing Company Shares Through Centralized Competitive Bidding

MaticHoleFiller · 2026-04-08T08:41:10+00:00

Hunan Nanxin Pharmaceutical Co., Ltd. announced that it has repurchased shares through centralized bidding, totaling 2,288,014 shares, accounting for 0.83% of the total share capital. The total amount of funds used for the repurchase is approximately RMB 19.25M, aimed at implementing equity incentives or employee stock ownership plans.

MaticHoleFiller

2026-04-08 08:41:10

Abstract generation in progress

Stock code: 688189 | Stock abbreviation: Nansun Pharmaceuticals | Announcement No.: 2026-013

Hunan Nansun Pharmaceuticals Co., Ltd. Announcement on the Progress of the Company’s Share Repurchase Conducted by Means of Centralized Competitive Trading

The board of directors of the Company and all its directors warrant that there are no false records, misleading statements, or material omissions in the contents of this announcement, and they assume legal responsibility for the authenticity, accuracy, and completeness of the contents of this announcement.

Key Points:

■

I. Basic Information on the Share Repurchase

Hunan Nansun Pharmaceuticals Co., Ltd. (hereinafter referred to as the “Company”) convened the 15th meeting of the second session of its board of directors on April 28, 2025, at which it considered and approved the “Proposal on Repurchasing the Company’s Shares by Means of Centralized Competitive Trading.” The Company agreed to repurchase the Company’s RMB ordinary shares (A shares) using its own funds or raised funds through centralized competitive trading, with an amount of not less than RMB 10 million (inclusive) and not more than RMB 20 million (inclusive), for the purpose of implementing an equity incentive plan or an employee stock ownership plan. The repurchase price shall not exceed RMB 9.53 per share (inclusive), and the repurchase period shall be within 12 months from the date on which the board of directors considered and approved the share repurchase plan. For details, please refer to the “Repurchase Report on Repurchasing Shares by Means of Centralized Competitive Trading” (Announcement No.: 2025-017) disclosed by the Company on April 30, 2025 on the website of the Shanghai Stock Exchange (www.sse.com.cn).

II. Progress of the Share Repurchase

In accordance with relevant provisions such as the “Rules for Share Repurchase of Listed Companies” and the “Self-Regulatory Guidelines No. 7 for Listed Companies on the Shanghai Stock Exchange—Share Repurchase” and other relevant regulations, during the share repurchase period, the Company shall, within the first three trading days of each month, announce the share repurchase progress as of the end of the previous month. The Company hereby announces the progress of the share repurchase as follows:

In March 2026, the Company repurchased 169,800 shares of the Company through the trading system of the Shanghai Stock Exchange by means of centralized competitive trading. This represents 0.06% of the Company’s total share capital of 274,400,000 shares. The highest transaction price for the repurchased shares was RMB 7.84 per share, and the lowest was RMB 7.77 per share. The total amount of funds paid was RMB 1,327,248.02 (excluding transaction expenses such as stamp duty, trading commissions, etc.).

As of March 31, 2026, the Company has cumulatively repurchased 2,288,014 shares of the Company through the trading system of the Shanghai Stock Exchange by means of centralized competitive trading. This represents 0.83% of the Company’s total share capital of 274,400,000 shares. The highest transaction price for the repurchased shares was RMB 8.92 per share, and the lowest was RMB 7.02 per share. The total amount of funds paid was RMB 19,245,862.56 (excluding transaction expenses such as stamp duty, trading commissions, etc.).

The above share repurchase complies with the requirements of applicable laws and regulations and with the Company’s share repurchase plan.

III. Other Matters

The Company will strictly comply with relevant provisions such as the “Rules for Share Repurchase of Listed Companies” and the “Self-Regulatory Guidelines No. 7 for Listed Companies on the Shanghai Stock Exchange—Share Repurchase,” and within the repurchase period will make and implement repurchase decisions when appropriate based on market conditions. Meanwhile, it will timely fulfill its information disclosure obligations in accordance with the progress of the share repurchase matters. Investors are kindly reminded to be mindful of investment risks.

This announcement is hereby given.

Board of Directors of Hunan Nansun Pharmaceuticals Co., Ltd.

April 2, 2026

Endless information and precise interpretation—available on the Sina Finance app

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.